| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Departments of Thoracic/Head and Neck Medical Oncology [J. M. K., J. S. L., F. R. K., L. M., R. C. M., A. B., D. L., R. L., W. K. H.], Thoracic and Cardiovascular Surgery [G. L. W.], Cancer Prevention [S. M. L., X. X.], Pathology [J. Y. R., B. L. K.], and Biostatistics [J. J. L.], and Division of Pathology and Laboratory Medicine [H. A. F.], University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Lung cancer remains the number one cause of cancer-related deaths in the United States. To reduce the mortality associated with this disease, individuals at risk must be identified prior to the development of lung cancer, and effective prevention strategies must be developed. One such strategy is to use retinoids like N-(4-hydroxyphenyl)retinamide (4-HPR), which has been found to possess chemopreventive activities in preclinical studies. In this study, 139 smokers were registered and 82 were randomized onto a double-blinded, placebo-controlled chemoprevention trial of 4-HPR administered p.o. (200 mg once daily). Of these, 70 participants were eligible for response evaluation. Biopsies were obtained at six predetermined sites in the bronchial tree from participants before and at the completion of 6 months of treatment. 4-HPR treatment had no measurable effect on histopathology (squamous metaplasia and dysplasia) in the bronchial epithelium of current smokers. 4-HPR was detected (104.5 ± 64.0 ng/ml, mean ± SD) in the serum of participants, supporting its potential bioavailability. Serum retinol levels decreased markedly (44% of placebo-treated patients) as a consequence of 4-HPR treatment. Notably, the mRNA level of retinoic acid receptor ß, which is typically increased by retinoid treatment, did not change in the bronchial epithelium of 4-HPR-treated participants. Clonal populations of bronchial epithelial cells were detected by analysis of loss of heterozygosity at putative tumor suppressor loci on chromosomes 3p, 9p, and 17p, and these changes were not altered by 4-HPR treatment. In conclusion, at this dose and schedule, 4-HPR was not effective in reversing squamous metaplasia, dysplasia, or genetic and phenotypic abnormalities in the bronchial epithelium of smokers.
This article has been cited by other articles:
|
|
 |
|
  K. Kelly, J. Kittelson, W. A. Franklin, T. C. Kennedy, C. E. Klein, R. L. Keith, E. C. Dempsey, M. Lewis, M. K. Jackson, F. R. Hirsch, et al. A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without {alpha} Tocopherol or Observation in Subjects at High Risk for Lung Cancer Cancer Prevention Research, May 1, 2009; 2(5): 440 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Keith Chemoprevention of Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Sabichi, S. P. Lerner, E. N. Atkinson, H. B. Grossman, N. P. Caraway, C. P. Dinney, D. F. Penson, S. Matin, A. Kamat, L. L. Pisters, et al. Phase III Prevention Trial of Fenretinide in Patients with Resected Non Muscle-Invasive Bladder Cancer Clin. Cancer Res., January 1, 2008; 14(1): 224 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gray, J. T. Mao, E. Szabo, M. Kelley, J. Kurie, and G. Bepler Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 56S - 68S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman, J. J. Lee, J. W. Martin, A. K. El-Naggar, X. Xu, D. M. Shin, M. Thomas, L. Mao, H. A. Fritsche Jr., X. Zhou, et al. Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia. Clin. Cancer Res., May 15, 2006; 12(10): 3109 - 3114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, Q. Wei, L.-E Wang, K. D. Aldape, Y. Cao, M. F. Okcu, K. R. Hess, R. El-Zein, M. R. Gilbert, S. Y. Woo, et al. Survival Prediction in Patients With Glioblastoma Multiforme by Human Telomerase Genetic Variation J. Clin. Oncol., April 1, 2006; 24(10): 1627 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Hirsch and S. M. Lippman Advances in the Biology of Lung Cancer Chemoprevention J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Khuri and R. Lotan Retinoids in Lung Cancer: Friend, Foe, or Fellow Traveler? J. Clin. Oncol., September 1, 2004; 22(17): 3435 - 3437. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Kim, H. Lee, H. Kim, Y. M. Shim, J. Han, J. Park, and D.-H. Kim Promoter Methylation of Retinoic Acid Receptor Beta 2 and the Development of Second Primary Lung Cancers in Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2004; 22(17): 3443 - 3450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Khuri and V. Cohen Molecularly Targeted Approaches to the Chemoprevention of Lung Cancer Clin. Cancer Res., June 15, 2004; 10(12): 4249S - 4253S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Tsao, E. S. Kim, and W. K. Hong Chemoprevention of Cancer CA Cancer J Clin, May 1, 2004; 54(3): 150 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Winterhalder, F. R. Hirsch, G. K. Kotantoulas, W. A. Franklin, and P. A. Bunn Jr Chemoprevention of lung cancer--from biology to clinical reality Ann. Onc., February 1, 2004; 15(2): 185 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Kurie, R. Lotan, J. J. Lee, J. S. Lee, R. C. Morice, D. D. Liu, X.-C. Xu, F. R. Khuri, J. Y. Ro, W. N. Hittelman, et al. Treatment of Former Smokers With 9-cis-Retinoic Acid Reverses Loss of Retinoic Acid Receptor-{beta} Expression in the Bronchial Epithelium: Results From a Randomized Placebo-Controlled Trial J Natl Cancer Inst, February 5, 2003; 95(3): 206 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Soria, X. Xu, D. D. Liu, J. J. Lee, J. Kurie, R. C. Morice, F. Khuri, L. Mao, W. K. Hong, and R. Lotan Retinoic Acid Receptor {beta} and Telomerase Catalytic Subunit Expression in Bronchial Epithelium of Heavy Smokers J Natl Cancer Inst, January 15, 2003; 95(2): 165 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zou, A.-T. Vlastos, L. Yang, J. Wang, M. Brewer, and M. Follen Effect of 4-Hydroxyphenylretinamide on Human Cervical Epithelial and Cancer Cell Lines Reproductive Sciences, January 1, 2003; 10(1): 41 - 48. [Abstract] [PDF]
|
|
|
|
 |
|
 J L Mulshine and R A Smith Lung cancer * 2: Screening and early diagnosis of lung cancer Thorax, December 1, 2002; 57(12): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]
|
|
|
|
|
|
S. Lam, C. MacAulay, J. C. le Riche, Y. Dyachkova, A. Coldman, M. Guillaud, E. Hawk, M.-O. Christen, and A. F. Gazdar A Randomized Phase IIb Trial of Anethole Dithiolethione in Smokers with Bronchial Dysplasia J Natl Cancer Inst, July 3, 2002; 94(13): 1001 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Soria, C. Moon, and L. Mao RESPONSE: Re: Effects of N-(4-Hydroxy-phenyl)retinamide on hTERT Expression in the Bronchial Epithelium of Cigarette Smokers J Natl Cancer Inst, June 19, 2002; 94(12): 950 - 951. [Full Text] [PDF]
|
|
|
|
|
|
F. Formelli Correspondence re: M. Follen et al., A Randomized Clinical Trial of 4-Hydroxyphenylretinamide for High-Grade Squamous Intraepithelial Lesions of the Cervix. Clin. Cancer Res., 7: 3356-3365, 2001 Clin. Cancer Res., May 1, 2002; 8(5): 1310 - 1312. [Full Text] [PDF]
|
|
|
|
|
|
M. Follen and H. A. Fritsche Reply Clin. Cancer Res., May 1, 2002; 8(5): 1313 - 1313. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Belinsky, W. A. Palmisano, F. D. Gilliland, L. A. Crooks, K. K. Divine, S. A. Winters, M. J. Grimes, H. J. Harms, C. S. Tellez, T. M. Smith, et al. Aberrant Promoter Methylation in Bronchial Epithelium and Sputum from Current and Former Smokers Cancer Res., April 1, 2002; 62(8): 2370 - 2377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bruno, C. Tenca, D. Saverino, E. Ciccone, and C. E. Grossi Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment Carcinogenesis, March 1, 2002; 23(3): 447 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Young and C. M. Wilson Cancer Prevention: Past, Present, and Future Clin. Cancer Res., January 1, 2002; 8(1): 11 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Follen, E. N. Atkinson, D. Schottenfeld, A. Malpica, L. West, S. Lippman, C. Zou, W. N. Hittelman, R. Lotan, and W. K. Hong A Randomized Clinical Trial of 4-Hydroxyphenylretinamide for High-Grade Squamous Intraepithelial Lesions of the Cervix Clin. Cancer Res., November 1, 2001; 7(11): 3356 - 3365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and M. R. Spitz Lung Cancer Chemoprevention: An Integrated Approach J. Clin. Oncol., September 15, 2001; 19(90001): 74s - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Pastorino Molecular Targeting: the New Challenge in Lung Cancer Prevention J Natl Cancer Inst, August 15, 2001; 93(16): 1190 - 1191. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Soria, C. Moon, L. Wang, W. N. Hittelman, S. J. Jang, S.-Y. Sun, J. J. Lee, D. Liu, J. M. Kurie, R. C. Morice, et al. Effects of N-(4-Hydroxyphenyl)retinamide on hTERT Expression in the Bronchial Epithelium of Cigarette Smokers J Natl Cancer Inst, August 15, 2001; 93(16): 1257 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Lee, D. Liu, J. S. Lee, J. M. Kurie, F. R. Khuri, H. Ibarguen, R. C. Morice, G. Walsh, J. Y. Ro, A. Broxson, et al. Long-Term Impact of Smoking on Lung Epithelial Proliferation in Current and Former Smokers J Natl Cancer Inst, July 18, 2001; 93(14): 1081 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gupta, R. Nines, K. A. Rodrigo, R. A. Aziz, P. S. Carlton, D. L. Gray, V. E. Steele, M. A. Morse, and G. D. Stoner Effects of Dietary N-(4-Hydroxyphenyl)retinamide on N-Nitrosomethylbenzylamine Metabolism and Esophageal Tumorigenesis in the Fischer 344 Rat J Natl Cancer Inst, July 4, 2001; 93(13): 990 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman, J. J. Lee, D. D. Karp, E. E. Vokes, S. E. Benner, G. E. Goodman, F. R. Khuri, R. Marks, R. J. Winn, W. Fry, et al. Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer J Natl Cancer Inst, April 18, 2001; 93(8): 605 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Hong, M. R. Spitz, and S. M. Lippman Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets J. Clin. Oncol., November 1, 2000; 18(90001): 9s - 18. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
